Century Therapeutics Q2 net loss $32.5M; cash runway into Q4 2027; CEO named Board Chair

Century Therapeutics, Inc.

2025-Q2 EPS reported $0.51 vs consensus -$0.38 ▲ beat (+233.0%)

Net loss of $32.5M for Q2 2025 (vs. $31.2M in Q2 2024); cash & equivalents $158.5M as of June 30.
Cash runway extended into Q4 2027 after workforce reduction completed July 2025.
CEO Brent Pfeiffenberger appointed Board Chair; Joseph Jimenez steps down, becomes special advisor.
CNTY-101 CALiPSO-1 trial dosing two patients; clinical data expected by year-end 2025.
CNTY-308 enters IND-enabling studies; clinical start planned in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.